medigraphic.com

2008, Number 3

<< Back Next >>

Enf Infec Microbiol 2008; 28 (3)

Antimicrobial susceptibility of microorganism isolates from comunity respiratory tract infections

Barriga AG, Mercado GNF, Alarcón ON, Arumir EC

Language: Spanish
References: 43
Page: 106-113
PDF size: 91.46 Kb.


ABSTRACT

Objective. To evaluate in vitro activity of amoxicilin, amoxicilin-clavulanic acid, cefalexin, cefdinir, cefixime, cefditoren, ceftibuten, cefuroxime, chlaritromycin and levofloxacin against 800 bacterial strains isolated from patients with acute respiratory infections.
Material and methods. Prospective study in 800 isolates of Streptococcus pneumoniae (285), Haemophilus influenzae (220), Streptococcus pyogenes (177), and Moraxella catarrhalis (118) from the same number of patients with acute respiratory infections, using a microdilution plate method to determine minimal inhibitory concentrations 50 and 90, and percents of sensitivity.
Results. 285 strains correspond to S. pneumoniae, 220 to H. influenzae, 177 to S. pyogenes, and 118 to M. catarrhalis, the most active of the twelve antimicrobials evaluated was ceftibuten, which shows the lowest MIC.
Conclusions. Ceftibuten is a good alternative therapeutic option in the treatment of community acute respiratory infections.


REFERENCES

  1. Barriga AG. “La globalización de las enfermedades infecciosas”. Rev. Med. IMSS 2003; 41 (5): 369-371

  2. Spellberg R, Guidos R, Gilbert D, Bradley J, Boucher WH, Scheld WM, Bartlett JG, Edwards J Jr. “The Epidemic of Antibiotic Resistant Infections: a call to action for the Medical Community from the Infectious Diseases Society of America”. Clinic Infect Dis. 2008; 46: 1791-1794

  3. Jacobs M. “Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children”. Pediatr Infec Dis J. 2003; 22: suplemento (8) S109-S119

  4. Leowski J. “Mortality from acute respiratory infections in children under five year of age: global estimates”. World Health Stat Q 1986; 39: 138-144

  5. Valdespino JL, García MA. “Consideraciones clínicoepidemiológicas de las infecciones respiratorias agudas y crónicas”, en: García ML, Giono S, Pacheco CR, Escobar A, Valdespino JL, ed. Infecciones respiratorias agudas y crónicas. México, D. F., INDRE, SSA 1994: 107-125

  6. Martínez MC, Muciño O, Peniche A, Ramírez ME, Gutiérrez G. “Infecciones respiratorias agudas en comunidades rurales mexicanas”. Achiv. Med. 1989; 20: 255-262

  7. World Health Organization. Bases técnicas para las recomendaciones de la OPS/OMS sobre el tratamiento de la neumonía en niños en el primer nivel de atención. Ginebra Suiza; Organización Mundial de la Salud: 1992 WHO/ARI/91.20/OPS/HCP/HCT/ARI/92.1

  8. Leaños M.B, Miranda N.M.G, Solórzano J.F, Ortiz O.L, Guiscafre G.H. “Prevalencia de colonización por Moraxella catarrhalis en portadores asintomáticos menores de seis años”. Sal. Púb. Méx. 2001; 43 (1): 27-31

  9. Vaca MMA, Sierra VMP, Bernal ADA. “Panorama epidemiológico de las infecciones respiratorias agudas en niños menores de cinco años de los Estados Unidos Mexicanos. Comparación con cinco países del Continente Americano”. Rev. Inst. Nal. Enf. Resp. Mex. 1999; 12 (2): 120-128

  10. Fernández-Roblas R, Esteban J, Gradea I y cols. “Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in the southern European countries”. Int Jour Antimicrob Agen 2004; 23 (3): 295-298

  11. Goosesens H. “Surveillance of Resistance Among Major Pathogens Causing Respiratory Tract Infections in the United States”. Infect Dis Clin Pract 2006; 14: 52-55

  12. Lipsitch M. “How Do Antimicrobial Agents Lead to Resistance in Pathogens Causing Acute Respiratory Tract Infections?” Infectious Diseases in Clin Pract 2006; 14 (4): S6-S10

  13. Doern CV, Jones RN, Pfaller MF, Kugler K. “Haemophilus influenzae and Moraxella catarrhalis from Patients with community-acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)”. Antim Ag Chem 1999; 43 (2): 385-389

  14. Tristram S, Jacobson M, Appelbaun P. “Antimicrobial Agents Resistance in Haemophilus influenza”. Clin Microb Rev 2007; 20 (2): 368-289

  15. Verdium CM, Hol C, Fleer A, Van Dijk H, Belkum A. “Moraxella catarrhalis: from emerging to established pathogen”. Clin Microb Rev. 2002; 15 (1): 125-144

  16. Aracil B, Gómez-Garcés JL, Ales JI. “Sensibilidad de Haemophilus influenzae aislados en España a 17 antimicrobianos de administración oral”. Enferm Infecc y Microbiol Clin 2003; (21): 131-136

  17. Reyes H, Guiscafre H, Muñoz O, Pérez-Cuevas R, Martínez H, Gutiérrez G. “Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea”. J Clin Epidemiol 1997; 50 (11): 1297-1304

  18. Reyes H, Muñoz O, Pérez-Cuevas R, Tome P, Libreros V, Gutiérrez G. “Patrones de prescripción terapéutica en infección respiratoria aguda y diarrea aguda en instituciones de salud (IMSS-SSA) V. Cumplimiento Terapéutico y desperdicio de medicamentos”. Gac. Méd. Mex. 1992; 128:543-548

  19. Pérez-Cuevas R, Muñoz O, Guiscafe H, Reyes H, Tomé P, Gutiérrez G. “Patrones de prescripción terapéutica en infecciones respiratoria aguda y diarrea aguda en dos instituciones de salud (IMSS-SSA) IV. Características de la prescripción médica”. Gac. Méd. Mex. 1992; 128 (5): 531-541

  20. Turnidge J, Paterson DL. “Setting and Revising Antibacterial Susceptibility Breakpoints”. Clin Microb Rev 2007; 20 (3): 391-408

  21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement (M100-S17) and Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria (M11-A7). 2007

  22. Isenberg HP. Clinical Microbiology Procedures Handbook 2004. 2nd Edition ASM Press. Washington, DC

  23. Lynne S. García. Update of the Clinical Microbiology Precedence Handbook 2007. 2nd Edition ASM Press. Washington, DC

  24. Murray PP, Barron EJ, Jorgensen JH. Landry MC, Pfaller MA. Manual of Clinical Microbiology 2007. 9th Edition. ASM Press. Washington, DC

  25. Delpiano L, Kabalan PB, Diaz C. V, Pinto AJ. “Características y costos directos de infecciones respiratorias agudas en niños de guarderías infantiles”. Rer. Chil. Infect. 2006; 23 (2): 128-133

  26. Weber TJ. “Appropriate use of Antimicrobial Drugs: A Better Prescription is needed”. JAMA 2005; 294 (18):2354-2356

  27. Bauerfeind A. “Comparative antimicrobial spectrum and activity of Ceftibuten against clinical isolates from West Germany”. Diagn Microbiol and Infect Dis. 1991; 14 (1): 63-74

  28. Doern GV. “In vitro activity of ceftibuten against Haemophilus influenzae and Moraxella catarrhalis”. Diagn Microbiol and Infect Dis. 1991; 14 (1): 75-7

  29. Fernández P, San Marín L. “Neumonía adquirida en la comunidad: Terapia secuencial de cefalosporinas intravenosa a cefalosporina oral”. Rev. Med. Chile 2000; 128 (3): 2-7

  30. Guay DR. “Ceftibuten: a new expanded-spectrum oral cephalosporin”. Ann Pharmacother 1997; 31 (9): 1O22-1033

  31. Jones RN, Barry AL. “Ceftibuten (7432-S, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta lactamase stability and broth microdilution quality control guidelines”. European Jour. Clin Microb Infect. Dis.1988; 7 (6): 802-807

  32. Jones RN. “Ceftibuten: a review of antimicrobial activity spectrum and other microbiologic features”. Pediat Infec Dis J 1995; 14 (7): Supl. S77-S83

  33. Bhatnagan S., Chandra J. “Ceftibuten”. Indian Pediatrics 1999: 36; 901-904.

  34. Verbist L, Jacobs J, Hens K. “Comparative antimicrobial activity of ceftibuten against multiple-resistant microorganisms from Belgium”. Diagn Microbiol and Infect Dis.1991; 1: 53-61

  35. Maioli E, Marchese A, Roveta S, Cagnacci S, Cavallini F, Cassanolli C, Guaico L, Debbia EA. “In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens”. J Chemother 2007; 19 (2): 152-160

  36. Schito GC, Nicoletti G. “Susceptibility of respiratory and urinary tract pathogens to ceftibuten and other compative drugs results of an Italian multicenter survey. The Italian Ceftibuten Study Group”. J Chemother 1994; 6 (2):92-98

  37. Wise R, Andrews JH, Ashby JP, Thornber P. “Ceftibuten in vitro activity against respiratory pathogens, betalactamase stability and mechanism of action”. J Antimicrob Chemother 1990; 26 (2): 209-213

  38. Krumpe P. “The penetration of ceftibuten into the respiratory tract”. Chest 1999; 116: 369-373

  39. Scaglione F. “Interpretation of middle ear fluid concentrations of antibiotics: comparison between cefixima and azythromycin”. BJCP. 1999; 47: 267-271

  40. Aydemir J. “In vitro activity of fluoroquinolonas against common respiratory pathogens”. West Indian med. J 2006;55 (1): 9-12

  41. Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Sato WH, Ng TK, Yam WC, Ng WW. “Increasing resistance of Streptococcus pneumoniae to fluoroquinolonas, results of Hong Kong multicenter study in 2000”. J Antimicrob Chemother 2001; 48: 659-665

  42. Chen DK, McGear, de Azebedo JC, Low DE “Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network”. N Engl J Med 1999; 341: 233-239

  43. Hutchinsen J. “Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia”. N Engl J Med 2002; 347(1): 66-67




2020     |     www.medigraphic.com